Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin’s Lymphomas

Reuters

05-29

<a href="https://laohu8.com/S/ESLA">Estrella Immunopharma</a> Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin's Lymphomas

Estrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS® T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529919302) on May 29, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2539257741"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539257741\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2539257741?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539257741","market":"nz","top_or_hot":-1,"title":"Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin’s Lymphomas","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ESLA\">Estrella Immunopharma</a> Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin's Lymphomas\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ESLAW\">Estrella Immunopharma Inc.</a>, a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS® T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529919302) on May 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin’s Lymphomas</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEstrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin’s Lymphomas\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-29 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ESLA\">Estrella Immunopharma</a> Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin's Lymphomas\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ESLAW\">Estrella Immunopharma Inc.</a>, a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS® T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529919302) on May 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL1FsY2c:1","article_id":"2539257741","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539257741","pubTimestamp":1748520090,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin's Lymphomas. Estrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Estrella Immunopharma推进STARLIGHT-1试验，开始对第二个队列使用EB103治疗晚期B细胞非霍奇金淋巴瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESLA":0.9},"content_text":"Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin's Lymphomas\n    \n\nEstrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS® T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529919302) on May 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}